Constant elimination half-life is usually used in first-order one-compartment pharmacokinetic models to assess human exposure to dioxin-like polychlorinated biphenyls (PCBs). However, hepatic clearance rates are usually lower for elders than for young people. In this study, levels of 12 dioxin-like PCBs were determined in blood samples collected in 2012 from 305 individuals from the general population. We estimated the historical daily intake of dioxin-like PCBs for individuals with a validated annual exponential decay function. Based on the blood levels and historical daily intake levels, and using the maximum likelihood estimation by running the first-order one-compartment pharmacokinetic model, elimination rates were optimized as exponential functions of age for PCB118, PCB157, PCB189 and PCB126; linear functions of age for PCB114, PCB123, PCB167 and PCB169; and constant functions of age for PCB105 and PCB156. With the exception of PCB105 and PCB156, half-lives generally increased with age for individuals from 24 to 50 years old: from 0.805 to 1.95 years for PCB189, 2.08–4.54 years for PCB157, 3.32–5.58 years for PCB126, 3.52–6.81 years for PCB123, 5.24–12.29 years for PCB169, 6.60–14.40 years for PCB114, 7.50–14.01 years for PCB118, and 9.97–21.97 years for PCB167. The half-lives of PCB105 (5.79 years) and PCB156 (15.1 years) were independent of age. Our research for the first time clarified the effects of age on the elimination rate of dioxin-like PCBs in individuals from the general population, thus reducing uncertainty in future health risk assessments.